Gossamer Bio, Inc. (NASDAQ:GOSS) is included in our list of the 10 most active penny stocks to buy<\/strong>.<\/p>\n As of March 16, 2026, Gossamer Bio, Inc. (NASDAQ:GOSS) has support from 44% of analysts who maintain a \u201cBuy\u201d rating for the stock. The consensus price target of $1.00 indicates an upside potential of 117.39%.<\/p>\n Amid an uncertain regulatory environment, analysts recently revised their forecasts for Gossamer Bio, Inc. (NASDAQ:GOSS)\u2019s primary therapy, seralutinib. This therapy is being developed for pulmonary arterial hypertension (PAH).<\/p>\n H.C. Wainwright & Co. maintained a \u201cBuy\u201d rating but lowered its price target for Gossamer Bio, Inc. (NASDAQ:GOSS) from $10 to $5 on March 6, 2026. A more cautious outlook on the program\u2019s development prospects led the firm to lower its probability of success for seralutinib in PAH from 70% to 50%.<\/p>\n Additionally, on March 5, 2026, Oppenheimer & Co. reiterated its \u201cOutperform\u201d rating while lowering its price target from $12 to $3. While citing short-term regulatory uncertainties, the firm pointed out that a June FDA interaction, Week 48 results, and future CT FRI substudy data might help reduce risk in seralutinib\u2019s approval pathway and potentially lead to a re-rating in the shares.<\/p>\n Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company developing treatments for immunology, inflammation, and oncology, notably GB001 for eosinophilic asthma. Established in 2015, it is based in San Diego, California.<\/p>\n While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/strong>.<\/p>\n<\/div>\n<\/div>